 Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) will present new findings from its ongoing phase II clinical trial at the American Association for Cancer Research Immuno-Oncology (AACR IO) conference in Los Angeles from 23-26 February.
The data will highlight how its experimental melanoma vaccine, SCIB1, is working in combination with two widely used cancer drugs, nivolumab and ipilimumab.
SCIB1 is a DNA-based cancer vaccine designed to train the immune system to recognise and destroy melanoma cells. The study, known as SCOPE, is testing SCIB1 alongside checkpoint inhibitors—drugs that help the immune system attack cancer more effectively.
Early results from 25 patients show promising signs, with 84% seeing their disease controlled, 80% remaining progression-free, and 20% experiencing a complete response, meaning no signs of cancer were detected.
The new data, to be presented at the AACR IO conference, provides deeper insight into how SCIB1 activates the body’s immune T cells to fight melanoma. Scancell believes these findings will support further development of the vaccine as a new treatment option for advanced melanoma.
"Presenting data showing vaccine-specific T cell responses at AACR IO is an important validation of SCIB1 efficacy in advanced melanoma," said Scancell CEO Phil L'Huillier.
"This data supports the latest findings from the phase II Scope trial, evaluating SCIB1 in combination with CPIs. We look forward to sharing the latest insights with leading industry experts at AACR IO." |
Scancell
@scancellpharma
·
5h
Joseph Chadwick, Translational Research Scientist, will be presenting safety and efficacy data from our Phase 2 SCOPE study in advanced #melanoma at #AACRIO25. Join him from 1:45-4:45PM PT to learn more.
Read the full press release: |
My services don't come cheap....but I help out when I can.... |
Astonishing Talent ....
You should have some stem cells harvested ... |
As far as I'm aware....there is only ONE poster on here who has accurately called the SCLP price...
.
That'll be the peep who understands markets....and knows exactly what he's doing.
.
Clue: It's not inane... 😂 😂
.
The market is a place of irony and complete contradiction..
.
All about intellectual honesty...you have it...or you don't ! |
Dragons den ...lol
.
Oh you think I need investors money..lol
.
Well ...I've just deposited a huge sum due to a little crypto coin that's just listed on the exchange.
.
Another one later this week could bring me another 7 figure amount.
.
I'm not even talking about my Bitcoin or other crypto holdings....
.
You're a relative pauper inane ...get over it.
.
You made your choice... live with it !! |
2tyke trust me when i say you are so good, i think you can pitch to Dragons Den ...
imagine if you got all the dragons onboard investing there money for them ..
you would own the show ....
the one chair Dragon ...
"Master Dragon"
Good Luck .... you could finally make money !! after all the effort practicing here |
I mean...what's up with those clowns on LSE ?
.
Why would 'Phil' ( whoever he is) buy shares in the company he probably works for ?
.
Talk about 'compounding' massive risk !
.
We've simply got to assume he has an higher IQ than inane.... |
Yes ..as expected....next leg down seems to be underway.... |
You seem to self harm |
Scinv_temp
Posts: 1,528
Price: 9.20
No Opinion
RE: ConferenceToday 08:28
Speak for yourself. My average is under 10.
---------------------------------------------------------------------------
what is this Game .... Guess your age ?
Put me down for 8 |
True. Nobody wants a moldy scientist. Seriously though, it is positive that this is no longer all about liar Lindy. It never really was anyway. |
its also good to see other Scientists within Scancell ... getting out and about
Joe Chadwick
Translational Research Scientist at Scancell | Immuno-Oncology |
Have you been at the magic mushrooms already? |
PFS:-The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. |
Moljen, I expect that we will not be at 9p when the data comes in for Modi-1 with doublet in RCC and iScib+.
Any bids of £1 billion would mean a share price of £1. |
Aha, a poster.
Take that, Doomies. |
Last year they were invited to present at a prestigious IO session at AACR, and they presented results from a year before. This year, with substantially more data and confidence, just a poster. This is what happens when you are unprofessional. |
we are at Mk4 with 5 in the clinic and 6 progressing 7 and 8 are sitting in the wings and sister of Mk4 is ready couple that with MK9 tcr and Mk 10 cell therapy
If you add all that up it is a Tea Service of Golden Chalice
of which the first $1.2 billion of the project is signed up .. two chairs at the table |
Hopefully we do something similar this year.
Bionomics shares soar almost 400% after positive phase IIb results from PTSD treatment
Published: 14:49 28 Sep 2023
ImmuPharma's stock increased by 300% in 2019 after the company signed a licensing deal for its lupus treatment
Celator Pharmaceuticals' stock increased by over 300% after the company announced that its drug Vyxeos, which treats a type of blood cancer, had tested well.
Possibly a nice takeover premium next year.
Amgen acquired Horizon Therapeutics at a 48% premium
Abbott Laboratories in its $2.8 billion acquisition of Advanced Medical Optics premium of 219%
Hewlett-Packard (HP) acquisition of Autonomy paid a premium of around 79% over the market price
Vertex Pharmaceuticals and Alpine Immune Sciences 67% above closing price
Eli Lilly and Morphic Therapeutics
87% above 30-day volume-weighted average price
Novartis and MorphoSys, 94% over average one-month price
Lundbeck and Longboard Pharmaceuticals, 54% above prior closing price
Ono Pharmaceutical and Deciphera Pharmaceuticals, 75% above prior closing price |
I Overview
Learn more
According to available data, the global adjuvant melanoma market is estimated to be a significant portion of the broader melanoma therapeutics market, with recent reports indicating a market size of around $7.4 billion in 2022, projected to grow to $18.62 billion by 2031, driven largely by the increasing adoption of immune checkpoint inhibitors like pembrolizumab and nivolumab as primary adjuvant therapies for high-risk melanoma patients.
Key points about the adjuvant melanoma market:
Dominant therapies:
Immune checkpoint inhibitors like pembrolizumab and nivolumab are currently the leading drugs in the adjuvant melanoma market due to their proven efficacy in improving recurrence-free survival in high-risk stage III melanoma patients.
Market growth drivers:
Increasing awareness about melanoma, advancements in early detection, and the development of more targeted and effective adjuvant therapies are driving market growth.
Clinical considerations:
Patient selection is crucial for adjuvant therapy, with stage III melanoma being the primary focus, and careful consideration of potential side effects associated with immunotherapy. |
I assume you know the market size for the Vaccine Ruck in this indication
which vaccine are you comparing it to ? |
yes its called standard of care ....
i assume the leach market is still taking a slice |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
